Plasma adenosine deaminase2, is a marker for human immunodeficiency virus‐1 seroconversion

John G. Niedzwicki, Kenneth H. Mayer, Elie Abushanab, Darrell R. Abernethy

Research output: Contribution to journalArticlepeer-review

Abstract

Plasma adenosine deaminase2, (ADA2) has recently been proposed to be a marker for human immunodeficiency virus‐1 (HIV) infection. We measured ADA2, levels in plasma from two groups of white homosexual males at 6‐month intervals for a total of 2.5 years. One group consisted of 6 subjects who seroconverted for HIV, and the other consisted of 8 HIV seropositive patients who progressed from asymptomatic (CDC Groups II/III) to symptomatic (CDC Group IV) disease. Seroconversion was associated with a significant increase in plasma ADA2 which persisted throughout follow‐up of 1.5 years. However, disease progression in HIV seropositive patients was not associated with any significant change in plasma ADA2 In conclusion, ADA2, may represent a unique marker for HIV seroconversion which does not change with later progression to symptomatic disease.

Original languageEnglish (US)
Pages (from-to)152-155
Number of pages4
JournalAmerican journal of hematology
Volume37
Issue number3
DOIs
StatePublished - Jul 1991

Keywords

  • HIV‐1
  • adenosine deaminase
  • human immunodeficiency virus

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Plasma adenosine deaminase<sub>2</sub>, is a marker for human immunodeficiency virus‐1 seroconversion'. Together they form a unique fingerprint.

Cite this